Diabetic Macular Edema - Global Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Diabetic Macular Edema - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Diabetic Macular Edema - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 20, 8, 7, 41 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered
- Diabetic Macular Edema - Overview
- Therapeutics Development
- Therapeutics Assessment
- Companies Involved in Therapeutics Development
- Drug Profiles
- Dormant Projects
- Discontinued Products
- Product Development Milestones
- 3SBio Inc
- Abpro Corp
- Aciont Inc
- Acucela Inc
- Aerie Pharmaceuticals Inc
- Aldeyra Therapeutics Inc
- Allergan Plc
- Allgenesis Biotherapeutics Inc
- Ampio Pharmaceuticals Inc
- Araim Pharmaceuticals Inc
- Ascentage Pharma Group Corp Ltd
- Boehringer Ingelheim GmbH
- Cell Medica Ltd
- Celon Pharma SA
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chiome Bioscience Inc
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- Elasmogen Ltd
- Exonate Ltd
- EyeGate Pharmaceuticals Inc
- EyeGene Inc
- Eyevensys SAS
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Gene Signal International SA
- Graybug Vision Inc
- Isarna Therapeutics GmbH
- Kalvista Pharmaceuticals Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- Momenta Pharmaceuticals Inc
- Novartis AG
- Ocular Therapeutix Inc
- Oculis SA
- OcuNexus Therapeutics Inc
- Ohr Pharmaceutical Inc
- Opthea Ltd
- Outlook Therapeutics Inc
- Oxurion NV
- Pfizer Inc
- PharmAbcine Inc
- Protheragen Inc
- Qilu Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- Rezolute Inc
- and more...
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ax62qj
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005313/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs,Endocrine and Metabolic Disorders Drugs,Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL DIABETES
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 06:14 AM/DISC: 05/28/2019 06:14 AM